Efficacy And Safety Of Sirolimus-Based Immunosuppression Regime In Hepatocellular Carcinoma Patients Received Liver Transplantation: A Meta-Analysis

Objectives To assess the efficacy and safety of Sirolimus-Based Immunosuppression regime among liver recipients with hepatocellular carcinomaMethods Literatures were retrived from PubMed,EMBASE,Cochrane Library, and CBM databases.Quantitative meta-analysis was performed on 5 qualified studies.Results Five studies with a total of 548 patients met the criteria and were subjected to analysis. Application of Sirolimus-Based Immunosuppression regime significantly improved 1-year (HR:0.49,95%CI=0.30-0.78, p=0.003),3-year(HR:0.33,95%CI=0.19-0.58,p<0.001)and 5-year(HR:0.37, 95%CI=0.20-0.68,p=0.001)recurrence-free survival rates.There was also significant improvement of 1-year overall survival(HR:0.49,95%CI=0.22-1.10, p=0.08) for Sirolimus-Based Immunosuppression regime.Sirolimus didn't increase risk of rejection (OR:0.997,95%CI=0.63-1.56,p=0.99)or hepatic artery thrombosis(OR:3.143,95%CI=0.331-29.813,p=0.318)Conclusion Sirolimus-Based Immunosuppression regime may play an important role in patients undergoing liver transplantation for hepatocellular carcinoma.